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are significantly correlated to the underactive detrusor in EDS patients with or
without OT.
Can we explain this by the conjunctive tissue modification due to EDS? There is
a strong correlation between underactive detrusor, respectively PVR and OT. So
we can’t conclude to any LUTS specific to EDS.
Conclusion.– Dysuria and PVR are frequent in EDS but strongly correlated with
the OT.
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Objective.– To determine in daily practice, the failure rate of treatment with
Botox1 300UI of NDO and analyze the causes of failure and their
predictors.
Method.– Retrospective (2002–2011) monocentric study of patients with
overactive bladder, treated with 300 IU Botox1 and self-catheterized. The
evaluation criteria were clinical, urodynamic and ultrasound.
The time to occurrence of failures was estimated by the Kaplan Meir. Groups
were compared by the log rank test and Cox model.
Results.– One hundred and eighty-three patients were included (165 SCI, 18
multiple sclerosis (MS)). At 3 years, 152 patients continued injections of
intravesical botulinum toxin (83%) and 138 patients after 5 years (75.4%).
We differentiated the true failures (32 patients), from discontinuation of
treatment for side effects, poor tolerance of injections or neurological
outcome.
In the group of MS, there was only one true failure, other patients discontinued
treatment for other reasons, including the worsening of the disease.
In the group of patients who failed treatment, we find significantly in univariate
analysis:
–leakages after first injection, at 3 years (p<0.0001) and at 5 years (p<0.0001);
–presence of febrile urinary tract infection after 1st injection, at 3 years
(p = 0.01);
–existence of detrusor overactivity after first injection, at 3 years (p = 0.05);
–poor compliance before first injection, at 5 years (p = 0.04);
–maximum detrusor pressure after first injection, at 3 years (p = 0.005) and at 5
years (p = 0.0004).
In multivariate analysis, the following were significantly predictive of failure:
leakages after 1st injection a t 3 years (p = 0.01) and at 5 years (p = 0.0004), sex
of patients at 5 years (p = 0,01).
The rate of symptomatic urinary tract infections was significantly reduced after
toxin injection (p < 0.0001).
Conclusion.– This study, which is representative of daily practice in a neuro-
urology center, confirmed the effectiveness and safety of injections of 300 IU of
Botox1. Some factors seem predictive of failure of intra-detrusor botulinum
toxin (i.e. leakage after first injection).
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Introduction.– The aim was to evaluate neurologic patients with stable and
capacitive bladder under injections of intravesical botulinum toxin who are
unable to perform self-intermittent catheterization through the native urethra
who need continent vesicostomy, without augmentation enterocystoplasty.
Patients.– We identified all patients with stable neurogenic bladder under
injection of botulinum toxin realizing self-catheterization or by a helper but
unable to achieve them through unrethra, that underwent a continent
vesicostomy between 2008 and 2012. Indication, surgical technique,
complications, voiding method and quality of life were analysed.
Results.– We considered four women suffering from spinal cord injury (one) or
multiple sclerosis (three), unable to achieve self-catheterization through urethra
because of functionnal loss of upper limbs or adductors spasticity or increase of
weight. The surgical technique was vesicostomy using the Mitrofanoff
principle, without enterocystoplasty, because of bladder stability under médical
treatment and comorbidities; the native bladder was fixed to the inner face of the
abdominal wall. The mean operation time was 188 min. Minor complications
(stoma stenosis and wound dehiscence) and quality of life were not different
from patients who underwent enterocystoplasty. One patient had a Bricker three
years after first surgery.
Conclusion.– Injection of botulinum toxine for overactive bladder seems to be
an alternative to enterocystoplasty when realizing continent cystostomy in
neurologic patients with comorbidities like multiple sclerosis. However,
evolutivity of the pathology may lead to a second surgery due to inability to
achieve catheterization through urethra or loss of efficiency of botulinum toxin.
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Objectives.– Augmentation enterocystoplasty (AE) is a third-line treatment for
neurogenic detrusor overactivity (NDO). When the outcome of an AE is
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